We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Nextgen | LSE:NGG | London | Ordinary Share | GB00B7JRYW03 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 78.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2019 to Jul 2024
TIDMNGG
RNS Number : 2725G
NextGen Group PLC
27 June 2012
27 June 2012
NextGen Group plc
("NextGen" or the "Company")
Statement re suspension of trading
NextGen Group Plc (AIM: NGG), the AIM listed company developing its own diagnostics product pipeline and providing diagnostic biomarker development services, announces that Klaus Rosenau, Chairman, is seriously ill following a heart attack. The Board's thoughts are very much with Klaus' family at this difficult time.
The Company is in the final stages of agreeing a fundraising with new investors to secure its ongoing working capital requirements, but Mr Rosenau's illness means that it is unclear when this may be consummated.
As a consequence, the Company has today requested that trading in the Company's ordinary shares on AIM should be suspended pending clarification of its financial position.
ENDS
For further details please contact:
Leif Hamoe
CFO
NextGen Group
Tel: +45 4033 4083
Barry McAleer PhD MBA
CEO
NextGen Sciences Inc and NextGen Sciences Dx Inc
Tel: +44 (0)7825 413 110
Jonathan Wright
Tel: + 44 (0)20 7107 8000
Seymour Pierce Limited
Notes to Editors:
NextGen Group Plc (AIM: NGG) is a developer of diagnostic markers and products through its US-based subsidiary, NextGen Sciences Dx Inc and is a provider of diagnostic biomarker development services for pharmaceutical and biotech companies globally through its second US-based subsidiary, NextGen Sciences Inc. Using advanced techniques, such as Multiple Reaction Monitoring (MRM) mass spectrometry analysis, the Company is developing a portfolio of robust assays for testing clinical samples for drug safety and efficacy, and the development of personalized treatment for patients.
NextGen Sciences Inc is a wholly owned, operational subsidiary of NextGen Group Plc and is headquartered in Ann Arbor, Michigan, USA. NextGen Sciences' range of services, which include biomarker discovery, assay development, validation and testing are employed by its customers as a key part of the biomarker-based drug and diagnostic development process.
NextGen Sciences Dx Inc is a wholly owned, operational subsidiary of NextGen Group Plc and is headquartered in Boston, Massachusetts, USA. NextGen Sciences Dx utilises the expertise of NextGen Sciences Inc to discover biomarkers and develop assays for point-of-care diagnostics, to assist in patient treatment, for selection of patients for clinical trials and to aid decision-making on efficacy determination for therapeutic development.
This information is provided by RNS
The company news service from the London Stock Exchange
END
SRSUBAURUAANUAR
1 Year Nextgen Chart |
1 Month Nextgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
